What type of study is this?

This is a Human Clinical Trial study.

September 16, 2025European PsychiatryOpen Access

Repurposing Clozapine: An Off-Label Approach to Target Impulsivity, Emotional Dysregulation, and Suicidality in Borderline Personality Disorder

View Full Paper

Ask AI

Bookmark

Authors

Clinical trial shows clozapine reduced impulsivity and emotional dysregulation in borderline personality disorder, suggesting new treatment options.

Clozapine significantly reduced impulsivity, emotional dysregulation, and suicidality in patients with borderline personality disorder.
A 40% reduction in RIPoST-40 scores and 70% reduction in Columbia Scale scores were observed at three months.
Clinical assessments were conducted at baseline and intervals up to three months, using specific scales for evaluation.
These findings recommend clozapine as a potential adjunct treatment, highlighting the need for further research with larger cohorts.

Firenzuoli et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark

Clinical trial shows clozapine reduced impulsivity and emotional dysregulation in borderline personality disorder, suggesting new treatment options.